Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02783768 · ClinicalTrials.gov registry record · Early Phase 1

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

A Early Phase 1 study, sponsored by Columbia University.

Completed
Registry status
Early Phase 1
Development phase
12
Enrollment target

NCT02783768 is a Early Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02783768, a Early Phase 1 study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Early Phase 1
Development phase
12 participants
Enrollment target

Study Summary

Determination of the acute pulmonary toxicities of e-cigarettes in young adults is of major public health importance, as e-cigarette vapor contains established toxicants that as hypothesized cause acute damage to the airways and the pulmonary microvasculature that may promote the development of CLD, for which there remain few effective therapies. The study therefore propose a pilot study using a randomized crossover design in ten healthy young adults to test the acute effects of a standardized e-cigarette exposure on two sensitive, safe, non-invasive imaging measures: (1) ventilation defects on hyperpolarized helium-enhanced magnetic resonance imaging, and (2) pulmonary microvascular blood flow on gadolinium-enhanced pulmonary magnetic resonance angiography.

Interventions

  • OTHER Sham
  • DRUG Gadolinium
  • DEVICE E-cigarette
  • DRUG Hyperpolarized 3-Helium

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-03-01
Est. Completion 2018-07-24
Phase Early Phase 1

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT02783768

The ClinicalTrials.gov registry entry for NCT02783768 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Sham is the first listed.

NCT02783768 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02783768 about?

NCT02783768 is a clinical study titled "Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study". Determination of the acute pulmonary toxicities of e-cigarettes in young adults is of major public health importance, as e-cigarette vapor contains established toxicants that as hypothesized cause acute damage to the airways and the pulmonary microvasculature that may promote the development of CLD,...

What is the current status of trial NCT02783768?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2017-03-01. Estimated completion is 2018-07-24.

What interventions are being tested in trial NCT02783768?

The interventions under investigation include: Sham (OTHER), Gadolinium (DRUG), E-cigarette (DEVICE), Hyperpolarized 3-Helium (DRUG).

Who is sponsoring clinical trial NCT02783768?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.